Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

• Status: Withdrawn
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess how oxytocin delivered intranasally changes regional brain blood flow measured by positron emission tomography (PET) in conjunction with oxygen-15 labeled water in persons with schizophrenia. The objective is to better our understanding of oxytocin's role in the modulation of social judgment in schizophrenia and provide more information as to potential uses of oxytocin or a similar drug analog in treating certain features of schizophrenia and other neuropsychiatric disorders.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Normal volunteers: Age range: 18-55 years of age

• Normal Volunteers: No psychiatric illness in self; no psychotic illness in first degree relatives

• Normal Volunteers: No previous history of substance dependence in last 6 months; no substance abuse in last month

• Normal Volunteers: No contraindication for MRI scanning (i.e. cardiac pacemaker, prosthesis)

• Normal Volunteers: Not pregnant

• Normal Volunteers: No major medical illness (e.g. seizure disorder) or medication that affects brain structure (e.g. steroids)

• Normal Volunteers: Participation in Healthy Subject Recruitment protocol (HP-00042350).

• Patient Volunteers: DSM-IV diagnosis of schizophrenia

• Patient Volunteers: Voluntary and competent to sign an informed consent

• Patient Volunteers: No contraindication for MRI scanning (i.e. cardiac pacemaker, prosthesis)

• Patient Volunteers: No previous history of substance dependence in last 6 months; no substance abuse in last month

• Patient Volunteers: Not pregnant

• Patient Volunteers: No major medical illness other than schizophrenia that affects brain structure (e.g. seizure disorder); not currently taking medication other than that for schizophrenia that affects brain structure (e.g. steroids)

• Patient Volunteers: No diagnosis of Major Depressive Disorder within last 6 months

• Patient Volunteers: SANS Asociality global score 2 or greater

• Patient Volunteers: No change in antipsychotic medication (type and dose) within the last 4 weeks

• Patient volunteers: Age range: 18-55 years of age

Exclusion Criteria:

• Normal Volunteers: Age outside of specified range -Normal Volunteers: Psychiatric illness in self; psychotic illness in first- degree relative

• Normal Volunteers: Previous history of substance dependence in last 6 months; substance abuse in last month

• Normal Volunteers: Contraindication for MRI scanning (i.e. cardiac pacemaker, prosthesis)

• Normal Volunteers: Pregnant

• Normal Volunteers: Major medical illness (e.g. seizure disorder) or medication that affects brain structure (e.g. steroids)

• Patient Volunteers: Age outside of specified range

• Patient Volunteers: Contraindication for MRI scanning (i.e. cardiac pacemaker, prosthesis)

• Patient Volunteers: History of substance dependence in last 6 months; substance abuse in last month

• Patient Volunteers: Pregnancy

• Patient Volunteers: Major medical illness other than schizophrenia that affects brain structure; currently taking medication other than that for schizophrenia that affects brain structure

• Patient Volunteers: Diagnosis of Major Depressive Disorder within last 6 months

• Patient Volunteers: SANS Asociality global score < 2

• Patient Volunteers: Change in antipsychotic medication (type and dose) within the last 4 weeks